In this issue: Knock on effects of the Valsartan recall, the future of...
Boehringer and Lilly report positive data from Tradjenta trial
Boehringer Ingelheim and Eli Lilly have reported positive results from the CAROLINA cardiovascular outcomes trial of Tradjenta (linagliptin) in type 2 diabetes patients.
Merck plans Phase III trials for Keytruda in prostate cancer
Merck has announced plans to launch three pivotal Phase III clinical trials for its immunotherapy Keytruda as a combination treatment for prostate cancer after the drug demonstrated anti-tumour activity in an early-stage trial.
Exelixis to assess new tumour-targeting candidate in Phase I trial
US-based biotechnology firm Exelixis is set to commence a Phase I clinical trial to evaluate its new compound XL092 intended for the treatment of various cancer types.
Merck and Pfizer combination therapy improves kidney cancer survival
Merck has reported positive results from an interim analysis of the KEYNOTE-426 trial evaluating its Keytruda in combination with Pfizer’s Inlyta (axitinib) as the first-line treatment for advanced or metastatic renal cell carcinoma (RCC).
Immunicum begins ilixadencel combination therapy in ILIAD trial
Pharmaceutical company Immunicum has started dosing patients in the Phase Ib/II ILIAD clinical trial of ilixadencel and checkpoint inhibitors (CPIs) combination to treat cancer.
Tisotumab vedotin shows promise in treating six cancer types
A Phase I/II global clinical trial demonstrated that a new drug called tisotumab vedotin (TV), which uses ‘Trojan horse’ approach to enter into tumour cells, can treat six different types of cancer.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.